Market Cap (In USD)
73.78 Million
Revenue (In USD)
-
Net Income (In USD)
-142.65 Million
Avg. Volume
843.32 Thousand
- Currency
- USD
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 0.8778-3.77
- PE
- -
- EPS
- -
- Beta Value
- 1.698
- ISIN
- US0070021086
- CUSIP
- 007002108
- CIK
- 1720580
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. Chen Schor BA, CPA, M.B.A.
- Employee Count
- -
- Website
- https://www.adicetbio.com
- Ipo Date
- 2018-01-26
- Details
- Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients. Its lead product in pipeline includes ADI-001, which is in Phase I clinical study for the treatment of non-Hodgkin's lymphoma. The company also engages in the development of ADI-002, which is undergoing preclinical studies for the treatment of various solid tumors. Adicet Bio, Inc. is based in Boston, Massachusetts.
More Stocks
-
HAL
-
BLUEJETBlue Jet Healthcare Limited
BLUEJET
-
3681V-cube, Inc.
3681
-
BASECouchbase, Inc.
BASE
-
079980Huvis Corporation
079980
-
AERAeeris Limited
AER
-
MAHA-AMaha Energy AB (publ)
MAHA-A
-
BOILBeyond Oil Ltd.
BOIL